Sobi successfully completes tender offer for all outstanding shares of Dova Pharmaceuticals
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that its indirect wholly owned subsidiary Dragonfly Acquisition Corp. (Dragonfly) has successfully completed its tender offer to purchase all outstanding shares of Dova Pharmaceuticals, Inc. (Dova) (NASDAQ: DOVA), for USD 27.50 per share, net to the seller thereof in cash, without interest and subject to any applicable withholding taxes, plus one non-transferable Contingent Value Right (CVR). The tender offer expired as scheduled at one minute after 11:59 p.m., Eastern Time (12:00 midnight), on November 8, 2019. As of